Gene therapy is a promising treatment option for several diseases and involves vectors, either viral or non-viral vectors.&nbsp;
&nbsp;
Out of the several viral vectors that have been used for delivering the genes of interest, the Adeno-associated viral (AAV) vector appears to be the safest and effective vehicle and can maintain long-term gene and protein expression following a single injection of the vector.&nbsp;
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Adeno-Associated Virus Vectors in Gene Therapy in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total prevalent cases of selected indications</li>
<li>Total indication wise eligible cases</li>
<li>Indication wise Treated Cases of AAV Gene Therapies&nbsp;</li>
</ul>
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Epidemiology&nbsp;
<ul>
<li>The total prevalent cases of selected indications for AAV Gene Therapies in 7MM were 2,718,559 in 2017.&nbsp;</li>
<li>The highest number of prevalent cases was in Germany, with 428,198 cases in 2017.&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc;" href="https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market" target="_blank" rel="noopener noreferrer">Adeno-Associated Virus Vectors in Gene Therapy Market</a>
The total market size of AAV-vector-based Gene Therapy in 7MM in 2019 was USD 428 million.
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Market Drivers
<ul>
<li>Ability to treat a broad array of conditions</li>
<li>AAV Capsid Selection and Optimization</li>
<li>Longer Transgene Expression</li>
</ul>
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Market Barriers
<ul>
<li>Shortcomings of AAV based Gene Therapies</li>
<li>Failures and risks associated with clinical trials&nbsp;</li>
</ul>
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Emerging Drugs
The emerging&nbsp;drugs of the Adeno-Associated Virus Vectors in the Gene Therapy market are&nbsp;
<ul>
<li>Valoctocogene Roxaparvovec (BMN 270)</li>
<li>RG6357 (SPK-8011)</li>
<li>Fidanacogene elaparvovec (SPK-9001/ PF-06838435)</li>
<li>AT-GTX-502/scAAV9.P546.CLN3</li>
<li>Timrepigene emparvovec/BIIB111/AAV2-REP1</li>
<li>SGT-001</li>
<li>FLT190</li>
<li>RGX-121</li>
</ul>
And many others.&nbsp;
&nbsp;
Adeno-Associated Virus Vectors in Gene Therapy Key Players
The key players in the Adeno-Associated Virus Vectors in Gene Therapy market are
<ul>
<li>BioMarin Pharmaceutical</li>
<li>Roche&nbsp;</li>
<li>Spark Therapeutics</li>
<li>Pfizer&nbsp;</li>
<li>Amicus Therapeutics</li>
<li>NightstaRx Ltd</li>
<li>Solid Biosciences</li>
<li>Freeline Therapeutics</li>
<li>Regenxbio</li>
</ul>
And many others.&nbsp;

Adeno-Associated Virus Vectors in Gene Therapy Market

Adeno-Associated Virus Vectors in Gene Therapy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.